MINERALYS THERAPEUTICS, INC. Proceeds from Issuance of Redeemable Convertible Preferred Stock
MINERALYS THERAPEUTICS, INC. (MLYS) reported Proceeds from Issuance of Redeemable Convertible Preferred Stock of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued
us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock · last filed 2023-05-15
- MINERALYS THERAPEUTICS, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. proceeds from issuance of redeemable convertible preferred stock for the quarter ending 2022-03-31 was $12.00M.
| Period end | Proceeds from Issuance of Redeemable Convertible Preferred Stock 3 month |
|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 |
| 2022-03-31 | $12.00M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |